Nikhil Mathur
Fund manager Nikhil Mathur: portfolio changes across the 1 scheme AMFI's scheme summary documents name them on, Oct 2026, by share count.
Equity.
1 with AMFI average AUM, July - September 2026; each scheme in full, not split between co-managers. Source: AMFI.
On a scheme named on today, as the fund house files it. Source: AMFI SSD.
People named on at least one of the same schemes.
| Scheme | Fund house | Category | AUM | Role, as filed | Since, as filed | As of |
|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund | HDFC Mutual Fund | Equity Scheme - Sectoral/ Thematic | ₹3,128 cr | — | — | 2 Nov 2026 |
From each scheme's summary document on AMFI's site (scheme details), as it stood on the date shown. How to read
Named on the same scheme's summary document; the number is how many schemes they share. Source: AMFI SSD.
- ₹346 cr
- ₹284 cr
- ₹244 cr
- ₹190 cr
- ₹174 cr
- ₹149 cr
- ₹136 cr
- ₹126 cr
- ₹123 cr
- ₹123 cr
| Ticker | Company | Value | % of equity held | Schemes holding |
|---|---|---|---|---|
| DIVISLAB | Divi's Laboratories Limited | ₹346 cr | 9.6 % | 1 |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹284 cr | 7.8 % | 1 |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹244 cr | 6.7 % | 1 |
| APOLLOHOSP | Apollo Hospitals Enterprise Limited | ₹190 cr | 5.3 % | 1 |
| ALKEM | Alkem Laboratories Limited | ₹174 cr | 4.8 % | 1 |
| CIPLA | Cipla Limited | ₹149 cr | 4.1 % | 1 |
| ACUTAAS | Acutaas Chemicals Limited | ₹136 cr | 3.7 % | 1 |
| MAXHEALTH | Max Healthcare Institute Limited | ₹126 cr | 3.5 % | 1 |
| ASTERDM | Aster DM Quality Care Limited | ₹123 cr | 3.4 % | 1 |
| LUPIN | Lupin Limited | ₹123 cr | 3.4 % | 1 |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹123 cr | 3.4 % | 1 |
| NEULANDLAB | Neuland Laboratories Limited | ₹108 cr | 3.0 % | 1 |
| SHILPAMED | Shilpa Medicare Ltd. | ₹107 cr | 3.0 % | 1 |
| ANTHEM | Anthem Biosciences Limited | ₹107 cr | 3.0 % | 1 |
| RUBICON | Rubicon Research Limited | ₹98.8 cr | 2.7 % | 1 |
The 15 largest holdings by market value, summed over the schemes this manager is named on today.
1 scheme has no filed start date, so no return is shown
Each scheme's direct-growth return over the dates filed for this manager, next to its category's average. Returns and averages are computed by this site from AMFI NAVs; they are not the fund house's figures. Past performance may not be sustained in future.
| Month | Schemes with a change | Stocks added | Stocks cut | Bought | Sold | Net |
|---|---|---|---|---|---|---|
| Oct 2026 | 1 | 12 | 3 | ₹319 cr | ₹72.8 cr | +₹246 cr |
| Sep 2026 | 1 | 13 | 2 | ₹347 cr | ₹118 cr | +₹229 cr |
| Aug 2026 | 1 | 10 | 1 | ₹235 cr | ₹6.9 cr | +₹228 cr |
| Jul 2026 | 1 | 9 | 0 | ₹310 cr | ₹0.00 cr | +₹310 cr |
| Jun 2026 | 1 | 6 | 1 | ₹154 cr | ₹74.8 cr | +₹79.4 cr |
| May 2026 | 1 | 8 | 3 | ₹214 cr | ₹104 cr | +₹110 cr |
| Apr 2026 | 1 | 7 | 7 | ₹129 cr | ₹123 cr | +₹5.8 cr |
| Mar 2026 | 1 | 6 | 1 | ₹48.7 cr | ₹11.2 cr | +₹37.5 cr |
| Feb 2026 | 1 | 6 | 1 | ₹69.1 cr | ₹39.3 cr | +₹29.8 cr |
| Jan 2026 | 1 | 9 | 4 | ₹46.4 cr | ₹87.1 cr | −₹40.8 cr |
| Dec 2025 | 1 | 7 | 6 | ₹90.8 cr | ₹92.4 cr | −₹1.6 cr |
| Nov 2025 | 1 | 5 | 4 | ₹65.3 cr | ₹50.2 cr | +₹15.1 cr |
Across the schemes this manager is named on today, by share count.
Changes seen in AMFI's documents
since 29 Sep 2026
Changes on this manager's schemes, by the date AMFI's document first showed them.
Added 12
12 stocks · largest 12 by value
| Stock | Schemes | Implied change, share count × price | Price 30 Oct 2026, 12‑month change |
|---|---|---|---|
| DRREDDY | 1 | +₹122 cr | ₹1,352.00 ▲ +12.9% |
| PARASHLTH | 1 | +₹85.7 cr | — |
| APOLLOHOSP | 1 | +₹56.6 cr | ₹8,448.00 ▲ +10.0% |
| ALKEM | 1 | +₹13.0 cr | ₹5,113.50 ▼ −7.1% |
| RUBICON | 1 | +₹11.1 cr | ₹1,610.50 ▲ +160.5% |
| MAXHEALTH | 1 | +₹9.2 cr | ₹860.00 ▼ −25.1% |
| SAILIFE | 1 | +₹7.4 cr | ₹1,557.50 ▲ +69.6% |
| SHILPAMED | 1 | +₹3.8 cr | ₹955.60 ▲ +170.8% |
| NEULANDLAB | 1 | +₹3.6 cr | ₹19,700.00 ▲ +19.6% |
| MEDANTA | 1 | +₹3.6 cr | ₹1,270.30 ▼ −3.1% |
| ASTERDM | 1 | +₹1.7 cr | ₹681.15 ▲ +0.5% |
| JLHL | 1 | +₹1.1 cr | ₹257.15 ▼ −19.0% |
Each scheme's change in shares at its month-end price, summed over this manager's schemes, Oct 2026.
Questions about Nikhil Mathur
from the figures on this pageWhat stocks are in Nikhil Mathur's portfolio?
The 1 scheme Nikhil Mathur manages held 38 stocks worth ₹3,621 cr at Oct 2026 end. Largest: Divi's Laboratories 9.6 %, Sun Pharmaceutical Industries 7.8 %, Dr. Reddy's Laboratories 6.7 %, Apollo Hospitals Enterprise 5.3 %, Alkem Laboratories 4.8 %. Divi's Laboratories mutual fund holdings · Sun Pharmaceutical Industries mutual fund holdings · Dr. Reddy's Laboratories mutual fund holdings
Which stocks did Nikhil Mathur buy and sell in Oct 2026?
In Oct 2026, Nikhil Mathur's schemes added to 12 stocks, largest Dr. Reddy's Laboratories (DRREDDY), Paras Healthcare (PARASHLTH), Apollo Hospitals Enterprise (APOLLOHOSP); cut 3, largest IPCA Laboratories (IPCALAB), Gland Pharma (GLAND), Cohance Lifesciences (COHANCE), by value at month-end prices.
Which mutual fund schemes does Nikhil Mathur manage?
AMFI's scheme summary documents name Nikhil Mathur (HDFC Mutual Fund) for 1 scheme: HDFC Pharma and Healthcare Fund. HDFC Pharma and Healthcare Fund portfolio